Clinical Trials Browser

Phase 1 × INDUSTRY × eprenetapopt × Clear all

NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Phase 1 Completed

51 enrolled 9 charts

Myeloid Malignancy

NCT00900614 2019-07-31

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Phase 1 Completed

GenitourinaryOther hematologic neoplasm

Prostatic Neoplasms, Hematologic Neoplasms